IGFI-I Inhibition and CD9 Modulation in Melanoma Immunotherapy

© 202 malignancies achieve a disease-free survival of more than 5 years. Therefore, immunotherapy directed against tumor-associated antigens might elicit specific immune responses that could eliminate minimal residual disease after surgery, radiotherapy and chemotherapy, or enhance the GVL effect after hematopoietic stem cell transplantation. This report summarizes hitherto identified and characterized LAA/ TAA as targets for T-cell-based immunotherapy. Current clinical peptide vaccination trials, especially targeting different epitopes of the Wilms’ tumor gene 1 (WT1), the proteinase-3 derived epitope peptide (PR1) and the receptor for hyaluronic acid mediated motility (RHAMM/CD168)-derived epitope R3, and perspectives but also limitations of immunotherapeutic approaches are discussed.